VC
XENE icon

Vivo Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Vivo Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-396,589
Closed -$4.5M – 58
2020
Q1 		$4.5M Buy
+396,589
New +$5.65M 0.41% 43
2019
Q3 		– Sell
-1,405,476
Closed -$13.9M – 29
2019
Q2 		$13.9M Hold
1,405,476
– – 1.3% 22
2019
Q1 		$14.3M Hold
1,405,476
– – 1.42% 19
2018
Q4 		$8.87M Hold
1,405,476
– – 1.13% 25
2018
Q3 		$18.6M Buy
+1,405,476
New +$16.3M 1.87% 18

Other funds holding XENE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vivo Capital's XENE Position: Q2 2020 in Review

Vivo Capital sold out of Xenon Pharmaceuticals (XENE) in Q2 2020, closing a stake of 396,589 shares — an estimated $4.5M sold.

Vivo Capital first reported a position in XENE in Q3 2018 and held it in 5 quarters. The position peaked at $18.6M in Q3 2018. 79 funds tracked by Wall St. Rank hold XENE as of Q2 2020.

  • Vivo Capital reported no remaining Xenon Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Vivo Capital sold 396,589 Xenon Pharmaceuticals shares in Q2 2020, an estimated $4.5M.
  • Vivo Capital first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 5 quarters.
  • Vivo Capital's Xenon Pharmaceuticals position peaked at $18.6M in Q3 2018.
  • 79 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2020.

Based on Vivo Capital's 13F filing for Q2 2020, filed 14 Aug 2020.